[PDF] European CHMP supports extension to licensed indication for lenalidomide (Revlimid®)

European Medicines Agency - EMA
European Medicines Agency
Publication date:
26 April 2013


The CHMP has adopted a positive opinion recommending approval of a new indication for lenalidomide: Treatment of transfusion-dependent anaemia due to low- or intermediate-1-risk MDS associated with isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.